Faults seen in cancer study funding

NEW YORK (Reuters Health) – It’s well-known that clinical trials of cancer treatments often can’t cover their costs. But a new study suggests that government-funded trials could take at least one cue from those backed by drug companies. In 2010, the Institute of Medicine (IOM) released a report saying that the U.S. system for conducting cancer clinical trials was approaching a “state of crisis” (see Reuters story of April 10, 2010). …